All In Biotech

Drug Trial Radar · NCT06346509

Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants

A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study of PORT-77 Administered Orally to Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

156

Actual

Start

Apr 8, 2024

Primary completion

Dec 27, 2025

Study completion Jan 20, 2026

Sponsor

Lead sponsor
Portal Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A First-in-Human 2-part, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose, and food effect, investigation of the administration of PORT-77 in healthy adult participants.

Conditions

  • Healthy Adult Participants

Interventions

  • PORT-77Drug

    Healthy adult participants will receive PORT 77.

  • PlaceboDrug

    Healthy adult participants will receive matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of PORT-77 (Part I)Time frame: Day 8
  2. Number of incidence and severity of AEs as a measure of safety and tolerability of PORT-77 (Part II and III)Time frame: Day 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.